The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.
-
Narrated by:
-
By:
About this listen
We love to hear from our listeners. Send us a message.
Helen Sabzevari, Ph.D., President and CEO of Precigen, joins Host, Erin Harris to discuss how the company utilizes gorilla adenovirus vectors. These vectors offer significant advantages in delivering large genetic payloads, a crucial factor in developing effective gene therapies. Sabzevari also discusses Precigen's recent BLA submission for PRGN-2012, which includes Phase 1/2 pivotal study results where over 50% of patients achieved Complete Response and more than 85% experienced decreased surgical interventions.
Subscribe to the podcast!
Apple | Spotify | YouTube
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet